SVB Leerink Maintains Market Perform on Illumina, Lowers Price Target to $420
SVB Leerink analyst Puneet Souda maintains Illumina (NASDAQ:ILMN) with a Market Perform and lowers the price target from $425 to $420.
Illumina Insider Sold $1.2M In Company Stock
Alexander Aravanis, SVP And Chief Technology Officer at Illumina (NASDAQ:ILMN), made a large insider sell on October 12, according to a new SEC filing.
OTR Global Downgrades Illumina to Mixed
OTR Global downgrades Illumina (NASDAQ:ILMN) from Positive to Mixed.
Illumina Says Randomized Trial Demonstrates Whole-Genome Sequencing Leads To Precision Care For Critically Ill Infants
Illumina, Inc. (NASDAQ:ILMN) scientists, together with investigators from five children's hospital across the US, have co-authored a study published today in JAMA Pediatrics reporting
UK’s NHS Launches World’s Largest Trial Of Blood Test For 50 Types
Britain’s National Health Service (NHS) will begin the world’s largest trial of Grail Inc’s flagship Galleri blood test that can be used…
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
Illumina Inc (NASDAQ:ILMN) and Merck & Co Inc (NYSE:MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic…
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Illumina, Inc. (NASDAQ:ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the
Workday And Lam Research Lead The QQQ
U.S. indices were trading higher Friday as investors eye Fed Chairman Powell's speech at the Jackson Hole Symposium and gauge Fed tapering policy.
Looking into Illumina’s Return on Capital Employed
Pulled from Benzinga Pro data Illumina (NASDAQ:ILMN) showed a loss in earnings since Q1, totaling $187.00 million. Sales, on the other hand, increased by 3.02% to $1.13 billion during Q2.